11月 2025
- 首頁
- Akouos
11月 2025Akouos的市場佔有率分析
Our Mission: Healthy Hearing Available to All.
We are a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.
Akouos(包含公司地區)
查看更多網站流量與參與度資訊- akouos.com
Akouos截至 11月 2025 的總收入為 25M - 50M
Akouos 熱門網域產生的總收入
Akouos 熱門網域 3 年內的總收入
Akouos 熱門網域的總收入
Akouos的熱門網域總造訪量
了解Akouos市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Akouos的熱門網域平均造訪時長
分析Akouos參與度指標。
過去 3 個月平均造訪時長
子公司細目
Akouos的熱門網域平均頁面瀏覽量
了解Akouos如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Akouos
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Akouos, Inc. had issues with possible breaches of fiduciary duty and other violations of law on Oct 18th '22.Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akouos, Inc. ("Akouos" or the "Company") (NASDAQ: AKUS ), in connection with the proposed tender offer for the Company by Eli Lilly and Company (NYSE: LLY ).
10月 21, 2022閱讀更多
新聞Lillyindia acquires Akouos, Inc. for $487M.Eli Lilly and Co will acquire genetic medicine developer Akouos Inc for about $487 million in cash as the drugmaker aims to bolster its arsenal of gene therapies that target a range of disabilities.
10月 18, 2022閱讀更多
新聞Akouos, Inc. hired Aaron Tward as chief scientific officer on Mar 1st '22.Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer.
3月 10, 2022閱讀更多
查看所有Akouos信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。